Magnetic Resonance Imaging in Multiple Sclerosis: The Role of Conventional Imaging

Neurologic Clinics

Volumn 29, Issue 2, 2011, Pages 343-356

  Sicotte, Nancy L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diagnosis; Magnetic resonance imaging; Multiple sclerosis; White matter lesions

Indexed keywords

BRAIN ATROPHY; DIAGNOSTIC IMAGING; GRAY MATTER; IMAGE ANALYSIS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE; WHITE MATTER;

BRAIN; BRAIN MAPPING; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PROGNOSIS;

EID: 79952825657     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2011.01.005     Document Type: Review

References (77)

1. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983, 13(3):227-231.
2. Schumacher F., Beeve G., Kibler F., et al. Problems of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965, 122:552-568.
3. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50(1):121-127.
4. Optic Neuritis Study Group Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008, 65(6):727-732.
5. Tintore M., Rovira A., Rio J., et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006, 67(6):968-972.
6. Paty D.W., Li D.K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993, 43(4):662-667.
7. Simon J.H., Jacobs L.D., Campion M., et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998, 43(1):79-87. [see comments].
8. Li D.K., Paty D.W. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999, 46(2):197-206.
9. Ge Y., Grossman R.I., Udupa J.K., et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 2000, 54(4):813-817.
10. Miller D.H., Khan O.A., Sheremata W.A., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003, 348(1):15-23.
11. Cohen J.A., Barkhof F., Comi G., et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362(5):402-415.
12. Filippi M., Yousry T., Baratti C., et al. Quantitative assessment of MRI lesion load in multiple sclerosis. A comparison of conventional spin-echo with fast fluid-attenuated inversion recovery. Brain 1996, 119:1349-1355.
13. Simon J.H., Li D., Traboulsee A., et al. Standardized MR imaging protocol for multiple sclerosis: consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol 2006, 27(2):455-461.
14. Barkhof F., Filippi M., Miller D.H., et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997, 120(Pt 11):2059-2069.
15. Sormani M.P., Bonzano L., Roccatagliata L., et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009, 65(3):268-275.
16. Miller D.H., Rudge P., Johnson G., et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988, 111(Pt 4):927-939.
17. Fisher M., Prichard J.W., Warach S. New magnetic resonance techniques for acute ischemic stroke. JAMA 1995, 274(11):908-911.
18. Polman C.H., Reingold S.C., Edan G., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the " McDonald Criteria" Ann Neurol 2005, 58(6):840-846.
19. Truyen L., van Waesberghe J.H., van Walderveen M.A., et al. Accumulation of hypointense lesions (" black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996, 47(6):1469-1476.
20. van Walderveen M.A., Kamphorst W., Scheltens P., et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998, 50(5):1282-1288.
21. Barkhof F., Calabresi P.A., Miller D.H., et al. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009, 5(5):256-266.
22. Cadavid D., Cheriyan J., Skurnick J., et al. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. J Neurol Neurosurg Psychiatry 2009, 80(12):1337-1343.
23. Li B.S., Regal J., Soher B.J., et al. Brain metabolite profiles of t1-hypointense lesions in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2003, 24(1):68-74.
24. Pozzilli C., Tomassini V., Marinelli F., et al. 'Gender gap' in multiple sclerosis: magnetic resonance imaging evidence. Eur J Neurol 2003, 10(1):95-97.
25. Bakshi R., Neema M., Healy B.C., et al. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol 2008, 65(11):1449-1453.
26. Edwards L.J., Tench C.R., Gilmore C.P., et al. Multiple sclerosis findings in the spinal cord. Expert Rev Neurother 2007, 7(9):1203-1211.
27. Bot J.C., Barkhof F., Polman C.H., et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004, 62(2):226-233.
28. Miller D.H., Leary S.M. Primary-progressive multiple sclerosis. Lancet Neurol 2007, 6(10):903-912.
29. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6(9):805-815.
30. Lennon V.A., Wingerchuk D.M., Kryzer T.J., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364(9451):2106-2112.
31. Jarius S., Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010, 6(7):383-392.
32. Simon J.H., Kleinschmidt-DeMasters B.K. Variants of multiple sclerosis. Neuroimaging Clin N Am 2008, 18(4):703-716. xi.
33. Li Y., Xie P., Lv F., et al. Brain magnetic resonance imaging abnormalities in neuromyelitis optica. Acta Neurol Scand 2008, 118(4):218-225.
34. Benedict R.H., Bruce J.M., Dwyer M.G., et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol 2006, 63(9):1301-1306.
35. Houtchens M.K., Benedict R.H., Killiany R., et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology 2007, 69(12):1213-1223.
36. Sicotte N.L., Kern K.C., Giesser B.S., et al. Regional hippocampal atrophy in multiple sclerosis. Brain 2008, 131(Pt 4):1134-1141.
37. Fisher E., Rudick R.A., Simon J.H., et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002, 59(9):1412-1420.
38. Zivadinov R., Bakshi R. Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging 2004, 14(Suppl 3):27S-35S.
39. De Stefano N., Giorgio A., Battaglini M., et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010, 74(23):1868-1876.
40. Bakshi R., Ariyaratana S., Benedict R.H., et al. Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. Arch Neurol 2001, 58(5):742-748.
41. Calabrese M., Battaglini M., Giorgio A., et al. Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis. Neurology 2010, 75(14):1234-1240.
42. Mainero C., Benner T., Radding A., et al. In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology 2009, 73(12):941-948.
43. Kutzelnigg A., Lassmann H. Cortical demyelination in multiple sclerosis: a substrate for cognitive deficits?. J Neurol Sci 2006, 245(1-2):123-126.
44. Koch M., Uyttenboogaart M., Polman S., et al. Seizures in multiple sclerosis. Epilepsia 2008, 49(6):948-953.
45. Geurts J.J., Bo L., Pouwels P.J., et al. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol 2005, 26(3):572-577.
46. Calabrese M., Agosta F., Rinaldi F., et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 2009, 66(9):1144-1150.
47. Bakshi R., Benedict R.H., Bermel R.A., et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 2002, 59(1):62-68.
48. Brass S.D., Chen N.K., Mulkern R.V., et al. Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging 2006, 17(1):31-40.
49. Malecki E.A., Devenyi A.G., Barron T.F., et al. Iron and manganese homeostasis in chronic liver disease: relationship to pallidal T1-weighted magnetic resonance signal hyperintensity. Neurotoxicology 1999, 20(4):647-652.
50. Haacke E.M., Makki M., Ge Y., et al. Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging 2009, 29(3):537-544.
51. Neema M., Arora A., Healy B.C., et al. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging 2009, 19(1):3-8.
52. O'Riordan J.I., Thompson A.J., Kingsley D.P., et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998, 121(Pt 3):495-503.
53. Jacobs L.D., Beck R.W., Simon J.H., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000, 343(13):898-904.
54. Comi G., Martinelli V., Rodegher M., et al. Effect of glatiramer acetate on conversion to clinically definite multiple\ sclerosis in patients with clinically isolated syndrome (PreCISe study): a\ randomised, double-blind, placebo-controlled trial. Lancet 2009, 374(9700):1503-1511.
55. Kappos L., Polman C.H., Freedman M.S., et al. Treatment with interferon beta-1b delays conversion to clinically definite and\ McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67(7):1242-1249.
56. Chard D.T., Dalton C.M., Swanton J., et al. MRI only conversion to multiple sclerosis following a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 2011, 82(2):176-179.
57. Miller D.H., Weinshenker B.G., Filippi M., et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008, 14(9):1157-1174.
58. Charil A., Yousry T.A., Rovaris M., et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of " no better explanation" Lancet Neurol 2006, 5(10):841-852.
59. Lebrun C., Bensa C., Debouverie M., et al. Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. J Neurol Neurosurg Psychiatry 2008, 79(2):195-198.
60. Okuda D.T., Mowry E.M., Beheshtian A., et al. Incidental MRI anomalies suggestive of multiple sclerosis. The radiologically isolated syndrome. Neurology 2009, 72(9):800-805.
61. Okuda D.T., Crabtree E., Mowry E.M., et al. Asymptomatic spinal cord lesions predict clinical progression in Radiologically Isolated Syndrome (RIS) subjects. Neurology 2010, 74(Suppl 2):A119.
62. Lebrun C., Bensa C., Debouverie M., et al. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. Arch Neurol 2009, 66(7):841-846.
63. Fisniku L.K., Brex P.A., Altmann D.R., et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008, 131(Pt 3):808-817.
64. Sormani M.P., Rovaris M., Comi G., et al. A reassessment of the plateauing relationship between T2 lesion load and disability in MS. Neurology 2009, 73(19):1538-1542.
65. Fisniku L.K., Chard D.T., Jackson J.S., et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008, 64(3):247-254.
66. Fisher E., Lee J.C., Nakamura K., et al. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008, 64(3):255-265.
67. Zhao Y., Petkau A.J., Traboulsee A., et al. Does MRI lesion activity regress in secondary progressive multiple sclerosis?. Mult Scler 2010, 16(4):434-442.
68. Li D.K., Held U., Petkau J., et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 2006, 66(9):1384-1389.
69. Rio J., Comabella M., Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009, 5(10):553-560.
70. Rovaris M. The definition of non-responder to multiple sclerosis treatment: neuroimaging markers. Neurol Sci 2008, 29(Suppl 2):S222-S224.
71. O'Riordan J.I., Losseff N.A., Phatouros C., et al. Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination. J Neurol Neurosurg Psychiatry 1998, 64(3):353-357.
72. Freedman M.S., Forrestal F.G. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study. Mult Scler 2008, 14(9):1234-1241.
73. Sahraian M.A., Radue E.W., Haller S., et al. Black holes in multiple sclerosis: definition, evolution, and clinical correlations. Acta Neurol Scand 2010, 122(1):1-8.
74. Calabrese M., Filippi M., Rovaris M., et al. Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study. Neuroimage 2008, 42(4):1324-1328.
75. Bagnato F., Jeffries N., Richert N.D., et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 2003, 126(Pt 8):1782-1789.
76. Giacomini P.S., Arnold D.L. Non-conventional MRI techniques for measuring neuroprotection, repair and plasticity in multiple sclerosis. Curr Opin Neurol 2008, 21(3):272-277.
77. Filippi M., Agosta F. Magnetic resonance techniques to quantify tissue damage, tissue repair, and functional cortical reorganization in multiple sclerosis. Prog Brain Res 2009, 175:465-482.